Skip to Main Content

Good morning. Elizabeth Cooney sitting in for Ed Silverman on what from here looks like a perfect summer day. Before you leave your laptop for the weekend, here are some news items to ponder. As Ed would say, fire up some stimulation and keep us in mind should you have spicy tips to share.

Even when all responses are “never” to six questions on a website co-sponsored by Biogen (BIIB), maker of the controversial new Alzheimer’s drug Aduhelm — such as, do you lose your train of thought or feel a bit more anxious —  the quiz still issues a “talk to your doctor” recommendation about the potential need for additional cognitive testing, Kaiser Health News says. The campaign — which also includes a detailed advertisement on The New York Times’ website, a Facebook page, and partnerships aimed at increasing the number of places where consumers can get cognitive testing — is drawing fire from critics.


In the latest look at clinical trial transparency, a new analysis found that only 26% of drug makers made results publicly available for all studies used to win approval for their medicines during a recent two-year period, STAT says. The analysis, which was published in BMJ Open, arrives amid concerns over disclosure and follows several scandals over safety or effectiveness data that were not publicly shared by drug makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.